Domov › Metastatická rakovina › Oklahoma › Oklahoma City
Klinické štúdie Metastatická rakovina v meste Oklahoma City, OK
16 štúdií pre Metastatická rakovina hľadá účastníkov v zariadeniach v meste Oklahoma City a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Prebieha náborFáza 1/2
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Prebieha náborFáza 2
- University of Oklahoma Health Sciences Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Prebieha náborFáza 1/2
- University of Oklahoma, Oklahoma City
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Prebieha náborFáza 1
- University of Oklahoma Health Sciences Center, Oklahoma City
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Prebieha náborFáza 3
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Prebieha náborFáza 1/2
- University of Oklahoma, Oklahoma City
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Prebieha náborFáza 2
- University of Oklahoma Health Sciences Center, Oklahoma City
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Prebieha náborFáza 1
- University of Oklahoma - Health Sciences Center, Oklahoma City
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
Prebieha náborFáza 1
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Prebieha náborFáza 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Prebieha náborFáza 1/2
- Stephenson Cancer Center, Oklahoma City
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Prebieha náborFáza 1/2
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Prebieha náborObservačná štúdia
- Mercy Hospital Oklahoma City, Oklahoma City
Circulating Tumor DNA Response In Urothelial Cancer
Prebieha náborFáza 2
- OU Health Stephenson Cancer Center, Oklahoma City
Spine Radiosurgery for Symptomatic Metastatic Neoplasms
Prebieha náborFáza 2
- OU Health Stephenson Cancer Center, Oklahoma City
A Study of NX-1607 in Adults With Advanced Malignancies
Prebieha náborFáza 1
- University of Oklahoma, Oklahoma City
Štúdie Metastatická rakovina v iných mestách
- Houston, TX104 štúdií
- New York City, NY93 štúdií
- Nashville, TN70 štúdií
- Boston, MA63 štúdií
- Los Angeles, CA57 štúdií
- St. Louis, MO54 štúdií
- Arlington, VA53 štúdií
- Philadelphia, PA46 štúdií
- Chicago, IL45 štúdií
- San Antonio, TX44 štúdií
- Washington, DC43 štúdií
- Dallas, TX42 štúdií
Iné štúdie v Oklahoma City
- Nemalobunkový karcinóm pľúc28 štúdií
- Rakovina vaječníkov28 štúdií
- Rakovina endometria25 štúdií
- Kolorektálny karcinóm22 štúdií
- Rakovina prostaty21 štúdií
- Rakovina pľúc19 štúdií
- Rakovina prsníka17 štúdií
- Rakovina (všetky typy)14 štúdií
- Akútna myeloidná leukémia14 štúdií
- Skvamóznocelulárny karcinóm hlavy a krku13 štúdií
- Rakovina močového mechúra11 štúdií
- Rakovina pankreasu11 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.